Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Should We Delay the Second COVID-19 Vaccine Dose?

Intissar Harizi, View ORCID ProfileSoulaimane Berkane, View ORCID ProfileAbdelhamid Tayebi
doi: https://doi.org/10.1101/2021.02.13.21251652
Intissar Harizi
1Department of Chemical and Biochemical Engineering, University of Western Ontario, 1151 Richmond St, London, ON N6A 3K7, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hintissa@uwo.ca
Soulaimane Berkane
2Department of Computer Science and Engineering, University of Quebec in Outaouais, 101 St-Jean Bosco, Gatineau, QC, J8X 3X7, Canada.
3Department of Electrical Engineering, Lakehead University, 955 Oliver Road, Thunder Bay, ON P7B 5E1, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Soulaimane Berkane
  • For correspondence: soulaimane.berkane@uqo.ca soulaimane.berkane@uqo.ca atayebi@lakeheadu.ca
Abdelhamid Tayebi
3Department of Electrical Engineering, Lakehead University, 955 Oliver Road, Thunder Bay, ON P7B 5E1, Canada.
4Department of Electrical and Computer Engineering, University of Western Quebec, 1151 Richmond St, London, ON N6A 3K7, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Abdelhamid Tayebi
  • For correspondence: atayebi@lakeheadu.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Due to the shortage in COVID-19 vaccine supplies and the alarming sanitary situation engendered by the COVID-19 pandemic, some countries have opted to delay the second dose of the COVID-19 vaccine for some period of time, aiming at getting the first dose of the vaccine to a large number of the population, before proceeding with the second doses [7, 6]. This strategy has sparked some heated debates world-wide for its pros and cons, and no clear consensus is reached among experts [5, 3]. Without taking side in this matter, we tried to answer the following question, from a pure mathematical perspective: should we delay the second dose of the vaccine or not?. We show that the answer to this question depends tightly on the efficacy of the first and the second COVID-19 vaccine doses. In particular, if the first dose is more than 50% efficient, the optimal procedure to maximize the number of effectively vaccinated sub-population is to delay the second vaccine as much as possible (the maximum period between the two doses prescribed by the clinical recommendations). On the other hand, if the efficacy of the first dose is less than 50% and the efficacy of the second dose exceeds a certain threshold, then it would be optimal to administer the second dose as quickly as possible (while respecting the minimum period between the two does as prescribed by the clinical recommendations). We provide explicitly the expression of this threshold as a function of the efficacy of first dose.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research work is supported by the National Research Council of Canada, under the grants NSERC-DG RGPIN-2020-04759 and NSERC-DG RGPIN-2020-0627.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

CER-UQO

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

There is not data associated with this paper.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted February 17, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Should We Delay the Second COVID-19 Vaccine Dose?
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Should We Delay the Second COVID-19 Vaccine Dose?
Intissar Harizi, Soulaimane Berkane, Abdelhamid Tayebi
medRxiv 2021.02.13.21251652; doi: https://doi.org/10.1101/2021.02.13.21251652
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Should We Delay the Second COVID-19 Vaccine Dose?
Intissar Harizi, Soulaimane Berkane, Abdelhamid Tayebi
medRxiv 2021.02.13.21251652; doi: https://doi.org/10.1101/2021.02.13.21251652

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (170)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8783)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1861)
  • Geriatric Medicine (178)
  • Health Economics (388)
  • Health Informatics (1290)
  • Health Policy (644)
  • Health Systems and Quality Improvement (491)
  • Hematology (207)
  • HIV/AIDS (393)
  • Infectious Diseases (except HIV/AIDS) (10557)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1754)
  • Nursing (103)
  • Nutrition (266)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (461)
  • Oncology (964)
  • Ophthalmology (282)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (117)
  • Palliative Medicine (43)
  • Pathology (264)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (219)
  • Psychiatry and Clinical Psychology (1843)
  • Public and Global Health (3982)
  • Radiology and Imaging (654)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (535)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)